Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Ivax Swallows Up Zenith


In Business This Week

IVAX SWALLOWS UP ZENITH

There's a new giant in the no-name-drug business. On Aug. 29, IVAX announced that it was planning to acquire Zenith Laboratories in exchange for about $600 million in stock. Together, the companies will have a stable of 63 generic drugs and more than 40 applications pending before the Food & Drug Administration. The price is high: more than six times Zenith's sales. But IVAX needs the clout in order to compete in managed care. "This is an important step in the long-run strategy for IVAX," says Viren Mehta of Mehta & Isaly. Conveniently, the purchase will also remove Zenith's new rival to IVAX' version of verapamil, a popular hypertension drug.EDITED BY KEITH H. HAMMONDS


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus